Clare Kelly

Title: Clare Kelly - Innovator in Preeclampsia Biomarkers

Introduction

Clare Kelly is a notable inventor based in Belfast, GB. She has made significant contributions to the field of medical diagnostics, particularly in the area of preeclampsia. Her innovative work focuses on the early detection of this serious condition that can affect pregnant women.

Latest Patents

Clare Kelly holds a patent for a groundbreaking invention titled "Biomarker for Preeclampsia." This invention relates to the use of the biomarker LRG1 as a predictive tool for preeclampsia from the first trimester of pregnancy. Elevated levels of leucine-rich alpha 2 glycoprotein 1 (LRG1) can indicate the risk of developing preeclampsia or other hypertensive disorders during pregnancy. The predictive test involves measuring LRG1 protein, peptide fragments, DNA, or RNA from various biological samples, including blood, plasma, serum, urine, saliva, or amniotic fluid. This invention provides a method and a test kit to assess the risk of preeclampsia in pregnant women, utilizing antibodies to measure levels of LRG1 in a sample. Clare Kelly has 1 patent to her name.

Career Highlights

Clare Kelly is affiliated with The Queen's University of Belfast, where she conducts her research and develops her innovative solutions. Her work has garnered attention for its potential to improve maternal health outcomes through early detection and intervention.

Collaborations

Clare has collaborated with esteemed colleagues, including Chris Watson and Timothy Lyons, to advance her research and innovations in the field of preeclampsia.

Conclusion

Clare Kelly's contributions to the field of medical diagnostics, particularly through her patent on biomarkers for preeclampsia, highlight her role as an innovator dedicated to improving health outcomes for pregnant women. Her work exemplifies the importance of early detection in managing pregnancy-related complications.